АЛГОРИТМЫ ВЕДЕНИЯ ПАЦИЕНТОВ С НЕЖЕЛАТЕЛЬНЫМИ ЯВЛЕНИЯМИ НА ФОНЕ ТЕРАПИИ ИНГИБИТОРАМИ ТИРОЗИНКИНАЗЫ EGFR
https://doi.org/10.21518/2079-701X-2017-6-38-50
Аннотация
Ингибиторы тирозинкиназы (ИТК) рецептора эпидермального фактора роста (EGFR), такие как гефитиниб, эрлотиниб и афатиниб, являются стандартом терапии первой линии местнораспространенного и метастатического немелкоклеточного рака легкого (НМРЛ) с частыми мутациями гена EGFR. Эти препараты более эффективны с точки зрения частоты ответа (ЧО) и выживаемости без прогрессирования (ВБП), менее токсичны и лучше переносятся, чем стандартная двухкомпонентная химиотерапия на основе препаратов платины. Наиболее частыми нежелательными явлениями (НЯ) являются желудочно-кишечные (ЖК) (диарея и стоматит/мукозит) и дерматологические (сыпь, сухость кожи и паронихия). Они, как правило, легкой степени тяжести, однако в некоторых случаях проявления могут быть средней и более степени тяжести и оказывают отрицательное влияние на качество жизни (КЖ) пациента и могут потребовать коррекции дозы или прекращения лечения. Управление НЯ, включая профилактические меры, поддерживающую терапию, временную отмену и снижение дозы препарата, имеет важное значение. Разработаны рекомендации по профилактике и лечению дерматологической токсичности (сыпь, сухость кожи и паронихия) и токсичности со стороны желудочно-кишечного тракта (диарея, стоматит и мукозит), связанных с терапией ИТК-EGFR. Эти рекомендации подробно описывают поддерживающую терапию, временную отмену лечения и снижение дозы препарата для ИТК-EGFR.
Об авторе
Д. Д. САКАЕВА
Республиканский клинический онкологический диспансер Министерства здравоохранения Республики Башкортостан
Россия
д.м.н., профессор
Россия
д.м.н., профессор
Список литературы
1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol., 2006, 7(7): 505-516.
2. Iivanainen E, Elenius K. ErbB targeted drugs and angiogenesis. Curr. Vasc. Pharmacol., 2010, 8(3): 421-431.
3. Rudloff U, Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle, 2010, 9(8): 1487-1503.
4. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer, 2009, 9(7): 463-475.
5. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non small cell lung cancer. Lung Cancer, 2010, 69(1): 1-12.
6. Licitra L, Bergamini C, Mirabile A, Granata R. Targeted therapy in head and neck cancer. Curr. Opin. Otolaryngol. Head Neck Surg., 2011, 19(2): 132-137.
7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351(4): 337-345.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-39.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nat Acad Sci, 2004, 101(36):13306-11.
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-500.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-57.
12. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single- agent iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol, 2012, 30(10): 1122-8.
13. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013, 24(1): 54-9.
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-8.
15. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Oka moto I, Seto T, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for pati ents with nonsmall cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol, 2012, 30(15 suppl): Abstr 7521.
16. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol, 2010, 11(2): 121-8.
17. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, openlabel, randomized, phase 3 study. Lancet Oncol, 2011, 12(8): 735-42.
18. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation- positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol, 2012, 13(3): 239-46.
19. Sequist LV, Yang JC, Yamamoto N, O’Byrne L, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27): 3327-34.
20. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open label, randomized phase 3 trial. Lancet Oncol, 2014, 15(2): 213-22.
21. European Medicines Agency. Summary of Product Characteristics – Tarceva (erlotinib). 2005 (2014 version accessed). cited, Available from: http: //www.ema.europa.eu.
22. European Medicines Agency. Summary of Product Characteristics – Iressa (gefitinib). 2009 (2014 version accessed). cited, Available from: http: //www.ema.europa.eu.
23. European Medicines Agency. Summary of Product Characteristics – Giotrif (afatinib). 2014. cited, Available from: http: //www.ema.europa.eu.
24. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6(10), 803–812 (2006).
25. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 2007, 12(5): 610-21.
26. Mario E Lacouture, Dirk Schadendorf, Chia-Yu Chu, Martina Uttenreuther-Fischer, Uz Stamm berger, Dennis O’Brien, Axel Hauschild. Dermato logic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev. Anticancer Ther, 2013, 13(6): 721-728.
27. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J. Drugs Dermatol, 2010, 9(10): 1229-1234.
28. Lu PH, Kuo TC, Chang KC, Chang CH, Chu CY. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Br. J. Dermatol., 2011, 164(1): 38-46.
29. Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities. Support. Care Cancer, 2011, 19(8): 1079-1095.
30. Lam KC, Mok TS. Targeted therapy: an evolving world of lung cancer. Respirology, 2011, 16(1): 13-21.
31. Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin. Transl. Oncol., 2011, 13(10): 710-714.
32. Lacouture ME, West DP, Tigue CC, Knox K, Bennett CL. Lacouture, Schadendorf, Chu et al. toxicities of targeted cancer therapies. Community Oncol, 2008, 5(7): 413-414.
33. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br. J. Dermatol., 2006, 155(4): 852-854.
34. Osio A, Mateus C, Soria JC et al. Cutaneous sideeffects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br. J. Dermatol., 2009, 161(3): 515-521.
35. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat., 2009, 114(3): 485-493.
36. Eskens FA, Mom CH, Planting AS et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer, 2008, 98(1): 80-85.
37. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol., 2010, 28(25): 3965-3972.
38. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol, 2012, 13: 528-538.
39. Seiwert TY, Fayette J, Cupissol D et al. A randomized, open-label, Phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck – final data. Presented at: the Multidisciplinary Head and Neck Cancer Symposium. Phoenix, AZ, USA, 26-28 January 2012.
40. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother. Pharmacol., 2012, 69: 891-899.
41. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 2007, 12(5): 610-621.
42. O’Keeffe P, Parrilli M, Lacouture M. Toxicity of targeted therapy: focus on rash and other dermatologic side effects. Oncol. Nurs. Ed., 2006, 20: 1-6.
43. Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitorinduced dermatologic toxicities on quality of life. Cancer, 2010, 116(16): 3916-3923.
44. Rudin CM, Liu W, Desai A et al. Pharmaco genomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol., 2008, 26(7): 1119-1127.
45. Witherspoon J, Wagner L, Rademaker A, West DP, Rosenbaum SE, Lacouture ME. Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor induced rash. J. Clin. Oncol., 2008, 26(Suppl. 15S): Abstract 9559.
46. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol, 2011, 22(3): 524-35.
47. Anon. Paronychia. [cited 17.07.2014]: Available from: http: //www.drugs.com/healthguide/paronychia.html.
48. NICE. Paronychia – acute. 2011 [cited 17.07.2014], Available from: http: //cks.nice.org.uk/paronychia-acute-!scenariorecommendation.
49. Rockwell PG. Acute and chronic paronychia. Am Fam Physician, 2001, 63(6): 1113-6.
50. Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Manage ment of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol, 2014 Dec, 21(6): 329-336. doi: 10.3747/co.21.2241.
51. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events. Ver 4.03. Bethesda, MD, 2010. [Available online at: http: //evs.nci.nih.gov/ftpl/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, cited April 29, 2012].
52. Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther, 2013, 13: 729-36.
53. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol, 2009, 2009: 567486.
54. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nature Clin Pract Oncol, 2008, 5: 268-78.
55. Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Bar rett KE. Epidermal growth factor inhi+bits Ca2+-dependent Cl-transport in T84 human colo nic epithelial cells. Am J Physiol, 1996, 271: C914-22.
56. Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care, 2013, 7: 162-7.
57. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol, 2011, 18: 126-38.
58. Thomas SK, Fossella FV, Liu D, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer, 2006, 7: 326-31.
59. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol, 2009, 45: e155-60.
60. Yang JCH, Sequist LV, O’Byrne KJ, et al. Epidermal growth factor receptor (egfr)– mediated adverse events in patients with EGFR mutation positive (EGFR M+) non-small cell lung cancer treated with afatinib [abstract 895]. Eur J Cancer, 2013, 49(suppl 2).
61. Crown JP, Burris HA 3rd, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat, 2008, 112(2): 317-325.
62. BC Cancer Agency (bcca). BCCA Guidelines for Manage-ment of Chemotherapy-Induced Diarrhea. Vancouver, BC: bcca, 2004. [Available online at: http: //www.bccancer.bc.ca/
63. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol, 2003,1: 35-46.
64. Yang JC, Sequist L, O’Byrne K et al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib. Eur J Cancer, 2013, 49(Suppl. 2): 895.
65. Bensinger W, Schubert M, Ang K, Brizel D, Brown E, Eilers J, et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J .Natl Compr Canc Netw, 2008, 6(Suppl 1): S1-21.
66. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer, 2003, 98(7): 1531-9.
67. Turhal NS, Erdal S, Karacay S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer, 2000, 8(1): 55-8.
68. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109(5): 820-31.
69. Lalla R, Sonis S, Peterson D. Management of oral mucositis in patients who have cancer. Dent Clin N Am. 2008, 52(1): 61-77.
70. Paz-Ares L, Tan E-H et al. Afatinib versus gefitinib in patients with EGFR mutation- positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX- Lung 7 trial. Annals of Oncology, 2017, 0: 1-9. doi: 10.1093/annonc/mdw611.
71. Soria J-C, Felip E, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. www.thelancet.com/oncology Published online July 6, 2015 http: //dx.doi.org/10.1016/S1470-2045(15)00006-6.
72. Yang JC-H, Sequist LV et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the ran- domized LUX-Lung 3 and 6 trials. Annals of Oncology, 2016, 00: 1-8. doi: 10.1093/annonc/mdw322.
Рецензия
Для цитирования:
САКАЕВА ДД. АЛГОРИТМЫ ВЕДЕНИЯ ПАЦИЕНТОВ С НЕЖЕЛАТЕЛЬНЫМИ ЯВЛЕНИЯМИ НА ФОНЕ ТЕРАПИИ ИНГИБИТОРАМИ ТИРОЗИНКИНАЗЫ EGFR. Медицинский Совет. 2017;(6):38-50. https://doi.org/10.21518/2079-701X-2017-6-38-50
For citation:
SAKAEVA DD. ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR. Meditsinskiy sovet = Medical Council. 2017;(6):38-50. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-38-50
Просмотров:
895
Послать статью по эл. почте 